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Abstract
Background: Injecting drug use is an increasingly important cause of HIV transmission in most countries
worldwide, especially in eastern Europe, South America, and east and southeast Asia. Among people actively
injecting drugs, provision of clean needles and opioid substitution reduce HIV-transmission. However, former
injecting drug users (fIDUs) are often overlooked as a high risk group for HIV transmission. We compared HIV risk
behavior among current and former injecting drug users (IDUs) in Indonesia, which has a rapidly growing HIV-
epidemic largely driven by injecting drug use.
Methods: Current and former IDUs were recruited by respondent driven sampling in an urban setting in Java, and
interviewed regarding drug use and HIV risk behavior using the European Addiction Severity Index and the Blood
Borne Virus Transmission Questionnaire. Drug use and HIV transmission risk behavior were compared between
current IDUs and former IDUs, using the Mann-Whitney and Pearson Chi-square test.
Results: Ninety-two out of 210 participants (44%) were self reported former IDUs. Risk behavior related to sex,
tattooing or piercing was common among current as well as former IDUs, 13% of former IDUs were still exposed
to contaminated injecting equipment. HIV-infection was high among former (66%) and current (60%) IDUs.
Conclusion: Former IDUs may contribute significantly to the HIV-epidemic in Indonesia, and HIV-prevention should
therefore also target this group, addressing sexual and other risk behavior.
Background
Worldwide, injecting drug use is estimated to account
for just less than one-third of new infections outside
sub-Saharan Africa [1]. HIV-prevention programs for
injecting drug users (IDUs) therefore put emphasis on
people actively injecting drugs, especially through needle
exchange or opioid replacement. Besides active IDUs,
people who have a previous history of injecting drug use
(former IDUs) are probably also an important risk
group for HIV transmission. However, relatively little is
known about this group. Sporadic studies from western
countries have shown that former IDUs (fIDUs) may
have a high risk of becoming HIV-infected or spreading
HIV to others [2,3]. To our knowledge, no studies on
fIDUs have been reported from low- or middle-income
countries.
Injecting drug use increased dramatically in the late
‘90s in Indonesia, acting as the main force driving the
HIV-epidemic. Among the general population, the pre-
valence of HIV-infection is still low (0.3%), but up to
50% or more of IDUs are already HIV-infected [4]. Drug
use is illegal in Indonesia, and harm reduction pro-
grams, although officially supported by the Indonesian
government, only reach a minority of IDUs. Apart from
sharing needles, sexual risk behavior is also common
among drug users [5]. In three large cities in Indonesia,
over two thirds of IDUs were sexually active, of whom
many reported having multiple partners (48%) and sex
with female sex workers (40%) in the preceding year.* Correspondence: shelly_bdg@yahoo.com1Department of Psychiatry, Faculty of Medicine, Padjajaran University/Hasan
Sadikin Hospital, Bandung, Indonesia
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Consistent condom use was only reported by 10% of
sexually active IDUs [5].
We know of no reported data concerning HIV risk
behavior among fIDUs in Indonesia, and fIDUs receive
very little attention in current prevention programs in
general. This may seriously limit the success of HIV-
prevention focusing on drug injection, as a considerable
number of IDUs change from injection to non-injection
drug administration or completely abstain from illicit
drug use [6]. The prevalence of HIV may be high in
fIDUs. Transmission of blood borne viruses may con-
tinue to occur through sexual behavior and/or by con-
taminating equipment that is subsequently used by
others for drug use, tattooing and/or piercing [2,7,8].
Furthermore, fIDUs may also play an important role
in transmitting HIV infections to the general population
because, compared with current IDUs (cIDUs), fIDUs
have more sexual contact with people who do not use
drugs [9,10]. Hopefully, a better characterization of for-
mer IDUs may contribute to improve HIV-prevention.
Therefore, the aim of the present study was to explore
the characteristics and the risk behavior of former IDUs
in Indonesia in comparison with current IDUs.
Methods
Setting and patients
From June to September 2008, 210 IDUs were recruited
in Bandung, the capital of West-Java and epicenter of
the epidemic of injecting drug use in Indonesia. Respon-
dent driven sampling, a form of peer recruitment, was
used for recruitment of IDUs from the community [11].
With help from local non-governmental organizations
involved in outreach to IDUs, three cIDUs and three
fIDUs from different parts of Bandung were selected to
act as ‘seeds’ for RDS and invited to a community clinic
which has a specific program for IDUs. Following their
inclusion in the study, these six seeds were asked to
recruit two other persons injecting drugs, either in the
last six months (cIDUs) or longer ago (fIDU), by giving
individually numbered coupons. IDUs presenting at the
community clinic with the coupons, were asked them-
selves to recruit two other (current or former) IDUs.
This process of recruitment continued until the desired
sample size was achieved. Numerical simulations have
shown that respondent driven sampling estimates con-
verge to the true values even if the seeds are not drawn
as desired [12].
As a part of the RDS process, an incentive was offered
for participating in the interview ($3) and for recruiting
two injecting drug using peers ($2 per eligible peer
recruited). After the initial seeds were recruited, only
those people who presented coupons were permitted to
participate in the study. The study was completely anon-
ymous, but to prevent the same participant from
entering the study twice, physical marks such as tattoos,
scars, or birth marks were recorded.
Only those candidates who were or had previously
been IDUs were eligible to be included in the study.
Two outreach workers from non-governmental harm
reduction organizations, both with a previous history of
drug use, confirmed that the respondents were indeed
IDUs. To this purpose they looked for possible needle
tracks, asked each respondent to demonstrate how he/
she injected drugs, and to clarify specific ‘slang’ used by
IDUs. All IDUs who passed this screening then provided
informed consent. The study was approved by the regio-
nal medical-ethical committee (The Health Research
Ethics Committee, Faculty of Medicine, Padjadjaran
University/Dr. Hasan Sadikin General Hospital Ban-
dung) and conducted within the context of program on
prevention and treatment of HIV in the context of
injecting drug use in Indonesia [13].
Assessment
The interview was done at the community health center
by trained interviewers who assured all participants that
their anonymity would be strictly maintained. All parti-
cipants who completed the interview session received a
coupon for free HIV, HBV, HCV and syphilis testing at
Hasan Sadikin hospital, Bandung. If found positive for
HIV, participants were offered CD4-cell counts, chest
X-ray and if needed, antiretroviral and/or syphilis treat-
ment, all free of charge.
The interviewers used two validated questionnaires:
the European Addiction Severity Index (EuropASI) and
the Blood Borne Virus Transmission Questionnaires
(BBV-TRAQ). The EuropASI is an adaptation of the
Addiction Severity Index (fifth version). It is a semi-
structured interview which takes about one hour, cover-
ing issues that may contribute to patients’ substance-
abuse problems, such as medical status, employment/
support status, drug/alcohol use, legal status, family
social relationship, and psychiatric problems [14]. Parti-
cipants are asked if they ever used a number of listed
drugs regularly (more than 3 times or 2 consecutive
days a week). For regularly used drugs, further informa-
tion is recorded including the first time the particular
drug was used, the duration of use in a life time, the fre-
quency of drug use in the previous 30 days, and drug
route of administration [14]. ASI has shown excellent
reliability and validity across a range of types of patients
and treatment settings in many countries [15]. For the
translation into Bahasa Indonesia, WHO translation
procedures were used [16].
The BBV-TRAQ questionnaire assesses how often
injecting drug users participate in specific injecting, sex-
ual and other risk-practices that may expose them to
blood-borne viruses. The instrument consists of
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34 questions divided in three sub-scales which measure
frequency of current risk behavior related to blood to
blood transfer (20 questions); sexual practices (8 ques-
tions); and other skin penetration activities (6 questions)
in the previous month. With respect to possible blood
to blood transfer, information is collected about contact
with contaminated needles and syringes, other drug
injecting equipment sharing and involvement of other
people in the drug preparation and injecting process.
Questions related to sexual risk behavior address unpro-
tected vaginal, anal, oral, and manual sex with other
people, with or without lubricant, and during menstrua-
tion or not. Other questions address skin penetration
risk behavior (tattooing and piercing), and shared use of
toothbrush, razor, and personal hygiene equipment. The
administration time for the instrument is short (around
15 minutes), and it has been shown good reliability and
validity [17,18].
Data analysis and statistics
A former IDU (fIDU) was defined as a person who
reported to have injected an illicit drug at some point in
his/her life, but not to have injected any drugs in the six
months prior to the interview (17, 18). A current IDU
(cIDU) was defined as a person who reported that he/
she had injected any type of illicit drug in the six
months prior to the interview [6,10]. Data were analyzed
both descriptively and inferentially. Descriptive data are
presented in terms of percentage, mean, and standard
deviation. Subjects engaging in at least one risk taking
behavior in a subscale of the BBV-TRAQ were regarded
as taking risks in that domain. Data were analyzed infer-
entially for differences between fIDUs and cIDUs. Pear-
son Chi-Square was used for dichotomous data and the
Mann-Whitney test for non-parametric continuous data.
All tests were two-sided, with a P-value of 0.05 or less
considered to indicate statistical significance. Analyses
were performed with the use of SPSS, version 11.5.
Results
Characteristics of IDUs in Bandung
A total of 210 IDUs were recruited, of whom 194 were
men (92%), 92 were fIDUs (44%), and 118 were cIDUs
(56%). Thirty-three out of 92 fIDUs (35.9%) were invited
by cIDUs, while 34 of 118 cIDUs (30.3%) were invited
by fIDUs, showing extensive social linking between the
two groups. Most of the demographic characteristics of
fIDUs and cIDUs did not differ, except for the length of
injecting drug and percentage of those who developed
AIDS (table 1). The mean age was 28 (±4) years and
most participants had graduated from senior high school
and had been employed at some point in the last 3years.
They had started using drugs at a young age (14 (± 3)
years). Injection of drugs had typically started 4 years
after non-injecting drug administration, and the period
of injecting drugs averaged 7 (± 4) years. Three quarters
of the participants had been tested for HIV and among
those tested 63% reported to be HIV-infected. There
was no significant association between the cumulative
years of drug injecting and HIV-status (P = 0.47). One
third of those who were HIV-infected reported to have
developed AIDS. Although cIDUs had injected for a
longer period than fIDUs, HIV-infected individuals in
the latter group more commonly reported having AIDS
(44% vs 18%; P = 0,01).
The most used substance by all participants was her-
oin. Ninety four percent of the total participants had at
some point used heroin regularly (at least three times a
week or for two consecutive days in a week for more
than 6 months). The other most used substances were
cannabis, benzodiazepines, and alcohol. More than three
quarters of participants had ever used or still used dif-
ferent drugs at the same time (poly drug use) and 70%
of the total IDUs had ever used or still used ampheta-
mine or methamphetamine regularly (median 2 years
(range less than 1 year until 15 years).
In the last 30 days, cIDUs had typically used more
drugs than fIDUs but neither cIDUs nor fIDUs reported
total abstinence in the last 30 days. The most used sub-
stances by fIDUs in the last 30 days were alcohol, licit
or illicit methadone/buprenorphine while cIDUs mostly
used licit or illicit methadone/buprenorphine, heroin,
benzodiazepines, and cannabis (table 2). Licit or illicit
use of methadone or buprenorphin cannot be differen-
tiated with the ASI.
Risk behavior related to transmission of blood-borne
viruses
Blood to blood transfer risk behavior was reported by
76% of cIDUs and 13% of fIDUs (X2 = 82,73; p < 0,01)
(table 3). Risk behavior of ninety cIDUs (76%) was
related to sharing of contaminated drug injecting
equipment. Current IDUs often reported behavior
associated with a very high risk of transmission of
blood-borne pathogens, including injecting with
another person’s used needle or syringe (reported by
15% of cIDUs), re-use of a needle or syringe taken out
of a shared disposal/sharps container without using
bleaching (9%), and sharp injuries from another per-
son’s used needle/syringe (15%). cIDUs also reported
behavior associated with a somewhat lower risk of
transmission. For example, they had exposure to con-
taminated drug injecting equipment included shared
use of a tourniquet (43%); injecting a drug prepared
with water previously used by another person (41%);
handling another person’s used needle or syringe when
wounded at his or her hand (34%); wiping his/her own
injection site with an object that had been used by
Iskandar et al. BMC Public Health 2010, 10:472
http://www.biomedcentral.com/1471-2458/10/472
Page 3 of 7
another person (27%); touching his/her own injection
site soon after ‘assisting’ another person with their
injection (26%); and injecting a drug that was prepared
immediately after ‘assisting’ another person with their
injection but without washing hands between activities
(26%). While fIDUs did not inject anymore, 13% still
had some risk of blood borne pathogens transmission,
especially through accidental needle stick injuries and
sucking or licking and other handling of another per-
son’s used needle/syringe. Interestingly, benzodiazepine
use was more common among IDUs engaging in risky
injecting behavior, 56% vs. 39% among cIDUs (X2 =
2,26; P = 0,19) and fIDUs (33% vs 9%; X2 = 5,99; P =
0,03). Injecting risk behavior was not associated with
use of alcohol, cannabis or methadone/buprenorphin
(data not shown).
Table 1 Sociodemographic characteristics of former and current injecting drug users
Total group (N = 210) fIDUs (N = 92) cIDUs (N = 118) P
Age, mean 27,8 (3,8) 28,1 (4,0) 27,5 (3,8) 0,64
Male gender 92% 89% 95% 0,12
Drug use 0,35
Age of first drug use, mean 14,0 (2,8) 14,2 (3,3) 13,8 (2,2) 0,31
Age of first drug injection, mean 18,0 (3,1) 18,4 (3,1) 17,8 (3,1) 0,17
Years of injecting in life time, mean 7,1 (3,8) 5,5 (3,6) 8,4 (3,4) < 0,01
Marital Status 0,35
Married/remarried 30% 36% 25%
Widowed 2% 3% 2%
Separated/divorced 11% 6% 14%
Never married 57% 55% 59%
Employment in the past 3 years 0,13
Full time 41% 48% 36%
Part-time 37% 36% 39%
Student 5% 5% 4%
Unemployed or housewife 17% 11% 21%
Education 0,48
Junior high school or less 6% 4% 7%
Senior high school 87% 87% 87%
Undergraduate or higher 7% 7% 6%
HIV-AIDS
Ever HIV-tested 75% 71% 78% 0,23
HIV-infected# 63% 66% 60% 0,47
Have developed AIDS## 30% 44% 18% 0,01
All data are presented in percentage unless stated otherwise
# n = 145; no data available for 12 subjects; ## n = 83; no data for 8 HIV-positive subjects
Table 2 Drug use among former and current injecting drug users
Kind of drug # Life time drug use Drug use in last 30 days
fIDUs (n = 92) cIDUs (n = 118) P fIDUs (n = 92) cIDUs (n = 118) P
Any use of alcohol 91% 97% 0,14 42% 59% 0,03
Alcohol, over threshold ## 66% 70% 0,66 26% 42% 0,02
Heroin 99% 100% 0,44 0% 79% < 0,01
Methadone or buprenorphine 33% 65% < 0,01 12% 53% < 0,01
Other opiates 22% 23% 0,87 1% 5% 0,14
Benzodiazepines 66% 79% 0,06 12% 52% < 0,01
Amphetamine 52% 53% 0,89 1% 9% 0,03
Cannabis 84% 87% 0,55 13% 47% < 0,01
Ecstasy (MDMA) 44% 37% 0,40 9% 14% 0,28
More than one substance 78% 83% 0,38 12% 55% < 0,01
# regular use (more than 3 times or 2 consecutive days a week). ## ≥ 3 drinks in 1-2 hours, ≥ 3 times or 2 consecutive days a week.
Note: Less than three participants used inhalant, hallucinogens or cocaine in the last 30 days.
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Sexual risk behavior of some form was reported by
56% of cIDUs and 42% of fIDUs (X2 = 3,57; P = 0,06).
The most common sexual risk behavior for cIDUs and
fIDUs was unprotected vaginal sex (47% respectively
35%, NS); reported unprotected anal sex was much
lower (8% respectively 7%, NS). No statistical significant
differences were found between former and current
IDUs regarding oral and manual sex (data not shown).
Excessive alcohol use was more common in IDUs enga-
ging in risky sexual behavior, both among cIDUs (51%
vs 33%; X2 = 3,86; P = 0,06) and fIDUs (46% vs 11%;
X2 = 14,14; P < 0.01). Other risk behavior such as tat-
tooing and piercing, which confer a much lower risk of
HIV transmission compared to needle-sharing, was
reported by half of all respondents (52% of fIDUs and
53% of cIDUs).
Discussion
This cross-sectional study from Indonesia shows a high
prevalence of HIV-infection among relatively young and
well-educated former and current IDUs. Current IDUs
obviously had much higher risks of viral transmission
related to injecting drugs, but also former IDUs had
risks related to blood to blood transmission. Impor-
tantly, both groups engaged in substantial risks related
to sexual transmission of HIV. Almost half of respon-
dents in our study were former IDUs, showing that this
group may contribute significantly to HIV transmission.
Injecting drug use is the main factor driving the HIV-
epidemic in Indonesia. In a large cohort of HIV patients
in our setting, two thirds had a history of IDU [19]. In
line with this finding, the prevalence of HIV-infection
among fIDUs and cIDUs in this study was high (66%
respectively 60%), similar or slightly higher compared
with previous local and national data [4]. The prevalence
of AIDS was higher among fIDUs; concern about their
general health or the development of AIDS may cause
them to move from injecting drugs [6].
Injecting with needles or syringe from other people
(15%) or from shared disposal/sharps containers without
bleaching (9%) was reported by a substantial proportion
of IDUs, although lower compared to previous research
in Indonesia (24% - 80%) [5,20]. The high rate of needle
stick injuries is no surprise given the fact 40% of IDUs
fail to discard used needles safely [21]. Risk related to
injecting drugs was especially high in cIDUs, but fIDUs
are experience certain things (e.g. needle sticks or shar-
ing of injecting equipment) which may have a low risk
of HIV-transmission, but which may pose a significiant
risk of transmitting HCV. This is important, as the pre-
valence of HCV is very high among IDUs in this setting;
among 633 HIV patients with a history of IDU 87.7%
were HCV-infected [19].
Both among current and former IDUs, sexual risk
behavior may contribute significantly to HIV transmis-
sion. Sexual risk behavior was equally high in both
groups, which is in contrast with previous studies
reporting associations between injecting drug use and
unsafe sex [22,23]. Condom use among IDUs has found
to be inconsistent and especially low with sex workers
and other risk groups for HIV transmission [20]. As
IDUs often have multiple sex partners, including sex
workers, HIV transmission may easily spread to people
outside the IDU community.
Heroin was the most frequently used drug among IDUs
in this sample but many reported use of cannabis, benzo-
diazepines and alcohol as well, in line with reports from
China, Thailand, Ukraine, Lithuania, and Poland [24].
Table 3 Risk behavior among former (fIDUs) and current injecting drug users (cIDUs) in the last 30 days
Risk Behavior fIDUs
(N = 92)
cIDUs
(N = 118)
X2 P
Blood-blood transfer, n (%) 13% 76% 82,73 <0,01
Suck or lick a filter which had been used by another person 4% 14% 5,81 0,02
Inject a drug prepared with water which had been used by another person 0% 41% 45,30 <0,01
Been injected by another person who had already injected or assisted in someone else’s injection 0% 20% 21,13 <0,01
Receive an accidental needle-stick/prick from another person’s used needle/syringe 3% 15% 7,56 <0,01
Re-use a needle/syringe taken out of a shared disposal/sharps container 0% 9% 8,26 <0,01
Sexual risk behavior, n (%) 42% 56% 3,57 0,06
Engage in unprotected vaginal sex with another person 35% 47% 2,98 0,08
Engage in unprotected vaginal sex with another person during menstruation 11% 20% 2,90 0,09
Engage in unprotected anal sex with another person 7% 8% 0,10 0,76
Tattoo or piercing, n (%) 52% 53% 0,02 0,90
Tattooed by someone who was not a professional tattooist 4% 15% 6,56 <0,01
Been pierced by someone who was not a professional piercer 10% 14% 0,96 0,327
Use another person’s toothbrush 3% 14% 7,45 <0,01
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The use of methadone or buprenorphine among cIDUs
was higher compared to fIDUs. The EuropASI question-
naire does not allow us to verify whether this was as part
of substitution treatment or not. Both drugs are officially
registered in Indonesia for substitution treatment but
illegal use is quite common. Buprenorphine injection has
been reported in many countries including Indonesia,
and can be regarded as a response to inadequate care,
rather than simply as misuse [25].
Alcohol abuse was common, and was associated with
risky sexual behavior, as has been reported previously
[26]. The same has been reported for methamphetamine
and amphetamine use [27], but this seems still relatively
rare in this setting. Our study also showed a high preva-
lence of tattooing and piercing in former and current
IDUs, both of which have may lead to transmission of
HIV and viral hepatitis [8,9,28].
This study suffers form the limitations of a cross-sec-
tional study in a population which is difficult to reach,
and the question is therefore how representative the
samples are. By using RDS, we tried to minimize this
risk [12,29]. Numerical simulations have shown that the
possible bias, even if the seeds are not drawn randomly,
is extremely small (0.3%) for all sample sizes greater
than 200 [12]. Still, some IDUs who are not in the social
networks with these participants can not be recruited
through respondent driven sampling [30].
Conclusions
In conclusion, this study from Indonesia shows that for-
mer IDUs, when compared to current IDUs, may have
similar high HIV prevalence rates and high sexual risk
behavior. Specific programs focusing on the reduction of
sexual risk behavior are needed among former and cur-
rent IDUs, in order to prevent further transmission to
the general community. Drug-use treatment and inter-
ventions that examine the relationship between drug use
and sexuality should be conducted. In addition, earlier
HIV treatment may lower transmission among IDUs by
reducing the ‘community viral load’[31]. We have
recently shown that patients with a history of injecting
drug use in our setting have a similar clinical and virolo-
gical response to anti-retroviral treatment compared to
non-IDUs [19]. Finally, evidence-based prevention
should also be targeted at schoolchildren and young
adolescents as injecting drug use starts at an early age
in this setting.
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